Advertisement

Changing trends and factors influencing anticoagulant use in patients with acute ischemic stroke and NVAF at discharge in the NOACs era

      Abstract

      Objectives

      We sought to explore the trends and influencing factors of the use of anticoagulants in patients with acute ischemic stroke and non-valvular atrial fibrillation (NVAF) at discharge in the era of novel oral anticoagulants (NOACs).

      Methods

      We recruited consecutive inpatients with acute ischemic stroke and NVAF in a registered study (NCT04080830) from January 2016 to December 2021. The relevant data of patients were collected. We compared the proportions of anticoagulant treatment at discharge before and after NOACs entered China's medical insurance system. The proportion of each antithrombotic status as well as anticoagulant agents at discharge in every year were calculated, and the trends during the study period were analyzed. The relevant factors affecting anticoagulant use at discharge were further analyzed.

      Results

      The proportion of anticoagulation at discharge increased significantly after NOACs entered China's medical insurance system in 2018 versus before (χ2 = 42.828, P < 0.001). There were statistically significant differences in antithrombotic status (χ2 = 69.954, P < 0.001) and in the proportion of different anticoagulant drugs (χ2 = 63.049, P<0.001) by year. Anticoagulant therapy (χ2 = 1.55, P = 0.671) and NOACs (χ2 = .178, P = 0.243) increased over 2016–2018 but was relatively stable during 2018–2021. Multivariate logistic regression analysis showed that age ≥75 years, coexisting cerebral artery stenosis, massive cerebral infarction and hemorrhagic transformation were independent risk factors affecting anticoagulants use (all P < 0.05).

      Conclusion

      NOACs have indeed improved anticoagulants use in patients with acute ischemic stroke and NVAF at discharge. However, some specific factors affect anticoagulation therapy use at discharge and hinder further improvement even in the NOACs era.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wang Z.
        • Chen Z.
        • Wang X.
        • et al.
        The disease burden of atrial fibrillation in China from a national cross-sectional survey.
        Am J Cardiol. 2018; 122: 793-798
        • Rohla M.
        • Weiss T.W.
        • Pecen L.
        • et al.
        Risk factors for thrombo-embolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational Prevention of thromboembolic events-European Registry in Atrial Fibrillation (PREFER in AF).
        BMJ Open. 2019; 9e022478
        • Xian Y.
        • Wu J.
        • O'Brien E.C.
        • et al.
        Real-world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study.
        BMJ. 2015; 351: h3786
        • Sun Y.
        • Hu D.
        • Chinese Investigators of GARFIELD
        Chinese subgroup analysis of the global anticoagulant registry in the FIELD (GARFIELD) registry in the patients with non-valvular atrial fibrillation.
        Zhong hua Xin Xue Guan Bing Za Zhi. 2014; 42: 846-850
        • Yang X.
        • Li Z.
        • Zhao X.
        • et al.
        Use of warfarin at discharge among acute ischemic stroke patients with nonvalvular atrial fibrillation in China.
        Stroke. 2016; 47: 464-470
        • Ruff C.T.
        • Giugliano R.P.
        • Braunwald E.
        • et al.
        Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials.
        Lancet. 2014; 383: 955-962
        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • et al.
        2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; 37: 2893-2962
        • Chiang C.E.
        • Okumura K.
        • Zhang S.
        • et al.
        2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.
        J Arrhythm. 2017; 33: 345-367
        • Lip G.Y.H.
        • Banerjee A.
        • Boriani G.
        • et al.
        Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report.
        Chest. 2018; 154: 1121-1201
        • Hindricks G.
        • Potpara T.
        • Dagres N.
        • et al.
        2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.
        Eur Heart J. 2021; 42: 373-498
        • January C.T.
        • Wann L.S.
        • Calkins H.
        • et al.
        2019 AHA/ACC/HRS focused update of the 2014AHA/ACC/HRS guideline for the management of patients with atrial fibrillation.
        Circulation. 2019; 140: 125-151
        • Hofmeijer J.
        • Worp H.B.
        • Kappelle L.J.
        Treatment of space-occupying cerebral infarction.
        Crit Care Med. 2003; 31: 617-625
        • Schulman S.
        • Kearon C.
        Subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
        J Thromb Haemost. 2005; 3: 692-694
        • Tomaselli G.F.
        • Mahaffey K.W.
        • Cuker A.
        2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American college of cardiology task force on expert consensus decision pathways.
        J Am Coll Cardio. 2017; 70: 3042-3067
        • Lin Y.P.
        • Tan T.Y.
        Do NOACs improve antithrombotic therapy in secondary stroke prevention in nonvalvular atrial fibrillation?.
        Medicine. 2015; 94 (Baltimore): e1627
        • No authors listed
        Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
        Lancet. 1993; 342: 1255-1262
        • Undas A.
        • Brummel-Ziedins K.E.
        • Mann K.G.
        Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.
        Blood. 2007; 109: 2285-2292
        • Manaktala R.
        • Kluger J.
        Role of antiplatelet therapy in stroke prevention in patients with atrial fibrillation [J].
        J AM Osteopath Assoc. 2017; 117: 761-771
        • Stroke Risk in Atrial Fibrillation Working Group
        Independent predictors of stroke in patients with atrial fibrillation: a systematic review.
        Neurology. 2007; 69: 546-554
        • Mant J.
        • Hobbs F.D.
        • Fletcher K.
        • et al.
        Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial.
        Lancet. 2007; 370: 493-503
        • Schäfer A.
        • Flierl U.
        • Berliner D.
        • Bauersachs
        Anticoagulants for stroke prevention in atrial fibrillation in elderly patients.
        J Cardiovasc Drugs Ther. 2020; 34: 555-568
        • Chao T.F.
        • Chiang C.E.
        • Liao J.N.
        • et al.
        Comparing the effectiveness and safety of nonvitamin K antagonist oral anticoagulants and warfarin in elderly asian patients with atrial fibrillation: a nationwide cohort study[J].
        Chest. 2020; 157: 1266-1277
        • Benbir G.
        • Uluduz D.
        • Ince B.
        • et al.
        Atherothrombotic ischemic stroke in patients with atrial fibrillation.
        Clin Neurol Neurosurg. 2007; 109: 485-490
        • Chang Y.J.
        • Ryu S.J.
        • Lin S.K.
        • et al.
        Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation.
        Cerebrovascular Dis. 2002; 13: 16-20
        • Sun W.
        • Li G.
        • Zeng X.
        • et al.
        Clinical and imaging characteristics of cerebral infarction in patients with nonvalvular atrial fibrillation combined with cerebral artery stenosis.
        J Atheroscler Thromb. 2018; 25: 720-732
        • Jolobe O.M.
        Coexistence of intracranial atherosclerosis and nonvalvular atrial fibrillation.
        Am J Med. 2014; 127: e39
        • Mant J.
        • Hobbs F.D.
        • Fletcher K.
        • et al.
        Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial.
        Lancet. 2007; 370: 493-503
        • Kim J.T.
        • Lee J.S.
        • Kim B.J.
        • et al.
        Effectiveness of adding antiplatelets to oral anticoagulants in patients with acute ischemic stroke with atrial fibrillation and concomitant large artery steno-occlusion.
        Transl Stroke Res. 2020; 11: 1322-1331
        • Park J.H.
        • Chung J.W.
        • Bang O.Y.
        • et al.
        Atherosclerotic burden and vascular risk in stroke patients with atrial fibrillation.
        Stroke. 2021; 52: 1662-1672
        • Chen G.
        • Wang A.
        • Zhao X.
        • et al.
        Frequency and risk factors of spontaneous hemorrhagic transformation following ischemic stroke on the initial brain CT or MRI: data from the China National Stroke Registry (CNSR).
        Neurol Res. 2016; 38: 538-544
        • Tan S.
        • Wang D.
        • Liu M.
        • et al.
        Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis.
        J Neurol. 2014; 261: 905-912
        • Kim J.T.
        • Heo S.H.
        • Park M.S.
        • et al.
        Use of antithrombotics after hemorrhagic transformation in acute ischemic stroke.
        PLoS One. 2014; 9: e89798
        • Paciaroni M.
        • Bandini F.
        • Agnelli G.
        • et al.
        Hemorrhagic transformation in patients with acute ischemic stroke and atrial fibrillation: time to initiation of oral anticoagulant therapy and outcomes.
        J Am Heart Assoc. 2018; 7e010133
        • Paciaroni M.
        • Agnelli G.
        • Micheli S.
        • et al.
        Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials.
        Stroke. 2007; 38: 423-430
        • Paciaroni M.
        • Agnelli G.
        • Falocci N.
        • et al.
        Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study.
        Stroke. 2015; 46: 2175-2182
        • Yaghi S.
        • Mistry E.
        • Liberman A.L.
        • et al.
        Anticoagulation type and early recurrence in cardioembolic stroke: the IAC study.
        Stroke. 2020; 51: 2724-2732